Amphastar Pharmaceuticals Inc vs Bumble Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while Bumble Inc trades at $2.82 (market cap $366.87M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2.4× Bumble Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | BMBL | |
|---|---|---|
Market Cap | $868.62M | $366.87M |
Sector | Health | Technology |
52-Week High | $30.81 | $7.17 |
52-Week Low | $16.87 | $2.70 |
Enterprise Value | $1.27B | $672.73M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.
The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →